Kaposi sarcoma associated with rituximab-based cytotoxic therapy

Alkan A., Yasar A., Toprak S.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.26, sa.1, ss.220-223, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1177/1078155219835592
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.220-223
  • Anahtar Kelimeler: Rituximab, Kaposi sarcoma, lymphoma, HHV-8
  • İnönü Üniversitesi Adresli: Evet

Özet

Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy.